Trump EO Right to Try pathway will produce at least one operational psychedelic patient access program before January 2027.

The Trump executive order created a pathway for seriously ill patients to access investigational psychedelic drugs — and Texas is moving fastest to build the first operational program.

EO directs FDA and DEA to establish Right to Try pathway. Texas has $50M allocated with end-2026 program target. Federal-state co-investment structure ($50M ARPA-H matching) creates strong incentive. Implementation lag for Schedule I Right to Try is unprecedented — 79% reflects strong momentum with real execution risk.